Document is current

Article History

Received: 2 July 2019

Accepted: 1 October 2019

First Online: 22 October 2019

Ethics approval and consent to participate

: The study protocol was approved by the Research Ethics Committee of National Cerebral an d Cardiovascular Center (Approval Number: M28-108) and the study was conducted in accordance with the principles of the Ethical Guidelines for Medical and Health Research Involving Human Subjects and the Declaration of Helsinki. This study is a retrospective analysis of the obtained data, carried out by the opt-out method of our hospital website.

: Not applicable.

: KH received grants, personal fees and non-financial support from Mitsubishi Tanabe Pharma Co., grants and personal fees from MSD Contribution, grants and personal fees from Sanofi K.K., grants and personal fees from Eli Lilly Japan K.K., grants from Novartis Pharma K.K., grants and personal fees from Takeda Pharmaceutical Co., grants and personal fees from Astellas Pharma Inc, grants from Daiichi Sankyo Co, grants from Amgen Inc., grants from Novo Nordisk Pharma, grants and personal fees from Kyowa Hakko Kirin Co., Ltd., personal fees from Ono Pharmaceutical Co, personal fees from Sumitomo Dainippon Pharma Co., and personal fees from Bayer Yakuhin, Ltd. CS received grants and personal fees from MSD Contribution, grants from Sanofi K.K., grants from Eli Lilly Japan K.K., grants from Novartis Pharma K.K, grants and personal fees from Takeda Pharmaceutical Co., personal fees from Ono Pharmaceutical Co., grants and non-financial support from Mitsubishi Tanabe Pharma Co. HM received grants from Eli Lilly Japan K.K. and Novartis Pharma K.K. YO, RK, MT, and TT declare that they have no competing interests.